Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, Padova 35131, Italy.
J Med Chem. 2012 Mar 8;55(5):2212-26. doi: 10.1021/jm201480u. Epub 2012 Feb 23.
Complexes [Au(III)X(2)(dtc-Sar-AA-O(t-Bu))] (AA = Gly, X = Br (1)/Cl (2); AA = Aib, X = Br (3)/Cl (4); AA = l-Phe, X = Br (5)/Cl (6)) were designed on purpose in order to obtain gold(III)-based anticancer peptidomimetics that might specifically target two peptide transporters (namely, PEPT1 and PEPT2) upregulated in several tumor cells. All the compounds were characterized by means of FT-IR and mono- and multidimensional NMR spectroscopy, and the crystal structure of [Au(III)Br(2)(dtc-Sar-Aib-O(t-Bu))] (3) was solved and refined. According to in vitro cytotoxicity studies, the Aib-containing complexes 3 and 4 turned out to be the most effective toward all the human tumor cell lines evaluated (PC3, DU145, 2008, C13, and L540), reporting IC(50) values much lower than that of cisplatin. Remarkably, they showed no cross-resistance with cisplatin itself and were proved to inhibit tumor cell proliferation by inducing either apoptosis or late apoptosis/necrosis depending on the cell lines. Biological results are here reported and discussed in terms of the structure-activity relationship.
为了获得可能专门针对几种肿瘤细胞中上调的两种肽转运体(即 PEPT1 和 PEPT2)的基于金(III)的抗癌肽模拟物,设计了复合物 [Au(III)X(2)(dtc-Sar-AA-O(t-Bu))](AA = Gly,X = Br(1)/Cl(2);AA = Aib,X = Br(3)/Cl(4);AA = l-Phe,X = Br(5)/Cl(6))。所有化合物均通过傅里叶变换红外光谱和单维和多维 NMR 光谱进行了表征,并解析和精修了 [Au(III)Br(2)(dtc-Sar-Aib-O(t-Bu))](3)的晶体结构。根据体外细胞毒性研究,含 Aib 的配合物 3 和 4 对所有评估的人肿瘤细胞系(PC3、DU145、2008、C13 和 L540)均显示出最高的有效性,其 IC50 值远低于顺铂。值得注意的是,它们与顺铂本身没有交叉耐药性,并且被证明通过诱导细胞凋亡或晚期凋亡/坏死来抑制肿瘤细胞增殖,具体取决于细胞系。本文报道了生物学结果,并根据构效关系进行了讨论。